Report Library
All Reports
Q4 2016 Outlook Report
October 05, 2016
In this report, we cover catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. We have also included a list of Large Impact catalysts in the drug and
device/diagnostic areas through Q4
2016. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease
group are provided.
Our Q3 2016 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. Biomedtracker Likelihood of Approval (LOA) opinions successfully predicted 46% of catalyst outcomes that occurred in Q3 2016.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.
Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.
Our Q3 2016 Outlook Report highlighted several high-impact catalysts. The results of these catalysts can be found on Page 5 of this report. Biomedtracker Likelihood of Approval (LOA) opinions successfully predicted 46% of catalyst outcomes that occurred in Q3 2016.
For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.
Like our report? Have any questions or feedback? Please let us know at askanalyst@sagientresearch.com.
For our disclosures, please read the Biomedtracker Research Standards.
| Indications Covered: |
Alzheimer's Disease (AD)
Bladder Cancer Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF) Community Acquired Pneumonia (CAP) (Antibacterial) Crohn's Disease Diabetes Mellitus, Type I Diabetes Mellitus, Type II Dyslipidemia / Hypercholesterolemia Friedreich's Ataxia Hepatitis B (HBV) Treatment (Antiviral) Hepatitis B Prevention (Vaccines, Antiviral) Immune Thrombocytopenic Purpura (ITP) Irritable Bowel Syndrome (IBS) Ischemic Stroke Moderate to Severe Pain Multiple Sclerosis (MS) Neuroendocrine Tumors (NET) Non-Small Cell Lung Cancer (NSCLC) Peripheral Arterial Disease (PAD) Rheumatoid Arthritis (RA) |
Additional Resources: